Skip to content
$
0.00
0
Cart
Search
(780) 448-0585
IOT.V 0.19 +0.01 +5.56%
|
OTCQB:IOTCF
Services
By Application
Anti-Adherence
Anti-Encrustation Testing
Antimicrobials
Environmental Bioburden Monitoring
Facility Water Testing
GMP Analytical Chemistry Testing Services
Medical Device Testing
MIC, MBC, MFC, Toxicology Testing
Microbiology Testing Services
Pharmaceutical & Drug Development
Stability Testing Services
Sterility Testing
By Method
Antimicrobial Effectiveness Testing USP <51>
BEST Assay™ Method
Environmental Bioburden Monitoring
GMP Analytical Chemistry Testing Services
MBEC Assay® Testing
Method Development and Validation Services
MIC, MBC, MFC, Toxicology Testing
By Industry
Compounding Pharmacies
Medical Device Testing
Pharmaceutical & Drug Development
Products
MBEC
InnovoSIL™ Silver
Resources
Investor Relations
Company
Our Team / History
Careers
Quality
Contact
Contact Us
News
April 24, 2025
SAWC Spring WHS 2025
April 16, 2025
Innovotech Inc. achieves record annual revenue and positive net income for 2024
March 31, 2025
Interim Financial Statements & MD&A for period ended 31 March 2025
February 3, 2025
Innovotech Inc. expands lab space and staff to meet its 2025 contract research pipeline
January 13, 2025
Innovotech Inc. appoints Mr. Brad Clark, CPA, CBV to its Board of Directors and creates new operating subsidiary to prepare for growth.
January 7, 2025
Innovotech Inc. Reports Issue of European Patent for Antimicrobial Silver Periodate Compounds Coated onto Polymers for Medical Devices
December 31, 2024
Annual Financial Statements & MD&A For the 2024 year ended December 31
November 19, 2024
Innovotech reports results for it’s third quarter and nine months ended 30 September 2024
November 5, 2024
Innovotech Closes Over-subscribed Private Placement and Completes Acquisition of Keystone Labs
October 30, 2024
Innovotech Announces Update to Keystone Acquisition and Private Placement
October 21, 2024
Innovotech signs Definitive Agreement to Acquire Keystone Labs
September 30, 2024
Interim Financial Statements & MD&A for period ended 30 September 2024
Page
1
Page
2
Page
3
Page
4
Page
5